Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187111 | 0.81 | KDM4E (0.54) | MAPTKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL348825 | 0.80 | KDM4E (0.53) | MAPTKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL347970 | 0.76 | KDM4E (0.42) | MAPTKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL348489 | 0.74 | KDM4E (0.44) | MAPTKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL347014 | 0.70 | MAPK14 (0.44) | MAPTKDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10154924 | 0.68 | KDM4E (0.44) | MAPTKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22435184 | 0.66 | MAPT (0.56) | MAPTKDM4ENPSR1MEN1KMT2A | |
| SCHEMBL30028627 | 0.66 | MAPT (0.68) | MAPTKDM4ENPSR1GAA | |
| SCHEMBL8985409 | 0.65 | MAPK14 (0.75) | MAPTKDM4EMEN1KMT2AGAA | |
| SCHEMBL24828267 | 0.65 | MAPT (0.67) | MAPTKDM4ENPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411001-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MAPT 4011/4885KDM4E 4010/4885CYP1A2 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.